NR3C2 and atrial fibrillation: Diuretics (73% vs. 45%), renin-angiotensin system (RAS) inhibitors (81% vs. 71%), and mineralocorticoid receptor antagonists (50% vs. 17%) were more often prescribed in AF/HF patients as compared to AF/non–HF patients (Figure S3; Supplementary Materials online).